Resistance to enfuvirtide, the first HIV fusion inhibitor

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 333-340

  Greenberg, Michael L ^a   Cammack, Nick ^b  

^a Trimeris Inc   (United States)

^b Roche   (United States)

Author keywords

Fusion inhibitors; gp41; Resistance

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; AMD 887; AMINO ACID; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APLAVIROC; BMS 043; CD4 IMMUNOGLOBULIN G2; ENFUVIRTIDE; FUSION INHIBITOR; GLYCOPROTEIN GP 41; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; PRO 2000; PROTEINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TNX 355; UNCLASSIFIED DRUG; VIRUS ADSORPTION INHIBITOR; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG WITHDRAWAL; GENE REARRANGEMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN CONFORMATION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ADSORPTION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS REPLICATION; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS;

EID: 4444375658     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh330     Document Type: Review

References (101)

1. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338, 853-60.
2. Staszewski, S., Morales- Ramirez, J., Tashima, K. T. et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 341, 1865-73.
3. Carr, A. (2003). Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery 2, 624-34.
4. Carpenter, C. C., Cooper, D. A., Fischl, M. A. et al. (2000). Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 283, 381-90.
5. Robbins, G. K., De Gruttola, V., Shafer, R. W. et al. (2003). Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349, 2293-303.
6. Shafer, R. W., Smeaton, L. M., Robbins, G. K. et al. (2003). Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349, 2304-15.
7. d'Arminio Monforte, A., Lepri, A. C., Rezza, G. et al. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 14, 499-507.
8. Lucas, G. M., Chaisson, R. E. & Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic, risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 131, 81-7.
9. Carr, A. & Cooper, D. A. (2000). Adverse effects of antiretroviral therapy. Lancet 356, 1423-30.
10. Brinkman, K., ter Hofstede, H. J., Burger, D. M. et al. (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12, 1735-44.
11. Lewis, W. & Dalakas, M. C. (1995). Mitochondrial toxicity of antiviral drugs. Nature Medicine 1, 417-22.
12. Fellay, J., Boubaker, K., Ledergerber, B. et al. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358, 1322-7.
13. Yeni, P. G., Hammer, S. M., Carpenter, C. C. et al. (2002). Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association 288, 222-35.
14. Carr, A., Samaras, K., Thorisdottir, A. et al. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipiclaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093-9.
15. Walli, R., Herfort, O., Michl, G. M. et al. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12, F167-73.
16. Yarasheski, K. E., Tebas, P., Sigmund, C. et al. (1999). Insulin resistance in HIV protease inhibitor-associated diabetes. Journal of Acquired Immune Deficiency Syndrome 21, 209-16.
17. Shafer, R. W., Winters, M. A., Palmer, S. et al. (1998). Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine 128, 906-11.
18. Earl, P. L., Doms, R. W. & Moss, B. (1990). Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences, USA 87, 648-52.
19. Gallaher, W. R., Ball, J. M., Garry, R. F. et al. (1989). A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Research and Human Retroviruses 5, 431-40.
20. Gallaher, W. R., Ball, J. M., Garry, R. F. et al. (1995). A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Research and Human Retroviruses 11, 191-202.
21. Kowalski, M., Potz, J., Basiripour, L. et al. (1987). Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237, 1351 -5.
22. Lasky, L. A., Nakamura, G., Smith, D. H. et al. (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975-85.
23. Peterson, A. & Seed, B. (1988). Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. Cell 54, 65-72.
24. Vermeire, K. & Schols, D. (2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. Journal of Leukocyte Biology 74, 667-75.
25. Kuritzkes, D. R., Jacobson, J., Powderly, W. G. et al. (2004). Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV Type 1. Journal of Infectious Diseases 189, 286-91.
26. Trkola, A., Pomales, A. B., Yuan, H. et al. (1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Journal of Virology 69, 6609 -17.
27. Nagashima, K. A., Thompson, D. A., Rosenfield, S. I. et al. (2001). Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. Journal of Infectious Diseases 183, 1121 -5.
28. Feng, Y., Broder, C. C., Kennedy, P. E. et al. (1996). HIV-1 entry cofactor, functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-7.
29. Dragic, T., Litwin, V., Allaway, G. P. et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-73.
30. Clapham, P. R. & McKnight, A. (2002). Cell surface receptors, virus entry and tropism of primate lentiviruses. Journal of General Virology 83, 1809-29.
31. Deng, H., Liu, R., Ellmeier, W. et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-6.
32. Dragic, T., Trkola, A., Thompson, D. A. et al. (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences, USA 97, 5639-44.
33. Strizki, J. M., Xu, S., Wagner, N. E. et al. (2001). SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences, USA 98, 12718-23.
34. Tremblay, C. L., Giguel, F., Kollmann, C. et al. (2002). Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrobial Agents and Chemotherapy 46, 1336-9.
35. Ketas, T. J., Klasse, P. J., Spenlehauer, C. et al. (2003). Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Research and Human Retroviruses 19, 177-86.
36. Trkola, A., Ketas, T. J., Nagashima, K. A. et al. (2001). Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology 75, 579-88.
37. Pozniak, A. L., Fatkenheuer, G., Johnson, M. et al. (2003). Effect of short term monotherapy with UK-427,857 on viral load in HIV-infected patients. In Proceedings of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 14-17 September 2003, Abstract H-443, p. 29. American Society for Microbiology, Washington, DC, USA.
38. Russel, D., Bakhtyari, A., Jazawi, R. P. et al. (2003). Multiple dose study to investigate the safety of UK-427,857 (100 mg or 300 mg) BID for 28 days in healthy males and females. In Proceedings of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 14-17 September 2003. Abstract H-874, p. 57. American Society for Microbiology, Washington DC, USA.
39. Tremblay, C. L., Kollmann, C., Giguel, F. et al. (2000). Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. Journal of Acquired Immune Deficiency Syndrome 25, 99-102.
40. Delwart, E. L., Mosialos, G. & Gilmore, T. (1990). Retroviral envelope glycoproteins contain a 'leucine zipper'-like repeat. AIDS Research and Human Retroviruses 6, 703-6.
41. Melikyan, G. B., Markosyan, R. M., Hemmati, H. et al. (2000). Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. Journal of Cell Biology 151, 413-23.
42. Munoz-Barroso, I., Salzwedel, K., Hunter, E. et al. (1999). Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. Journal of Virology 73, 6089-92.
43. Weissenhorn, W., Wharton, S. A., Calder, L. J. et al. (1996). The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO Journal 15, 1507-14.
44. Weissenhorn, W., Dessen, A., Harrison, S. C. et al. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-30.
45. Weissenhorn, W., Dessen, A., Calder, L. J. et al. (1999). Structural basis for membrane fusion by enveloped viruses. Molecular Membrane Biology 16, 3-9.
46. Chen, C. H., Matthews, T. J., McDanal, C. B. et al. (1995). A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. Journal of Virology 69, 3771-7.
47. Kliger, Y., Gallo, S. A., Peisajovich, S. G. et al. (2001). Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. Journal of Biological Chemistry 276, 1391-7.
48. Wild, C., Greenwell, T. & Matthews, T. (1993). A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Research and Human Retroviruses 9, 1051-3.
49. Wild, C. T., Shugars, D. C., Greenwell, T. K. et al. (1994). Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences, USA 91, 9770-4.
50. Chen, R. Y., Kilby, J. M. & Saag, M. S. (2002). Enfuvirtide. Expert Opinion in Investigational Drugs 11, 1837-43.
51. Kilby, J. M. & Eron, J. J. (2003). Novel therapies based on mechanisms of HIV-1 cell entry. New England Journal of Medicine 348, 2228-38.
52. LaBonte, J., Lebbos, J. & Kirkpatrick, P. (2003). Enfuvirtide. Nature Reviews Drug Discovery 2, 345-6.
53. Moyle, G. (2003). Stopping HIV fusion with enfuvirtide, the first step to extracellular HAART. Journal of Antimicrobial Chemotherapy 51, 213-7.
54. Kilby, J. M., Hopkins, S., Venetta, T. M. et al. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 4, 1302-7.
55. Kilby, J. M., Lalezari, J. P., Eron, J. J. et al. (2002). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Research and Human Retroviruses 18, 685-93.
56. Lalezari, J. P., Henry, K., O'Hearn, M. et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 348, 2175-85.
57. Lalezari, J. P., Eron, J. J., Carlson, M. et al. (2003). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17, 691-8.
58. Lazzarin, A., Clotet, B., Cooper, D. et al. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia. New England Journal of Medicine 348, 2186-95.
59. Church, J. A., Cunningham, C., Hughes, M. et al. (2002). Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatric Infectious Disease Journal 21, 653-9.
60. Katlama, C., Arastéh, K., Clotet, B. et al. (2003). Enfuvirtide TORO studies, 48 week results confirm 24 week findings. Antiviral Therapy 8, Suppl. 1, LB02.
61. Trottier, B., Arastéh, K., Henry, K. et al. (2003). Durability of response of enfuvirtide through 48 weeks in the TORO trials. In Proceedings of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 14-17 September 2003, Abstract H-835, p. 55. American Society for Microbiology, Washington, DC, USA.
62. Chan, D. C., Fass, D., Berger, J. M. et al. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-73.
63. Eckert, D. M., Malashkevich, V. N., Hong, L. H. et al. (1999). Inhibiting HIV-1 entry, discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103-15.
64. Williams, G. C., Liu, A., Knipp, G. et al. (2002). Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrobial Agents and Chemotherapy 46, 3456-62.
65. Wijnholds, J., Mol, C. A., van Deemter, L. et al. (2000). Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Sciences, USA 97, 7476-81.
66. Zhang, X., Patel, I. H., Lalezari, J. et al. (2003). Assessment of metabolic inhibition potential of enfuvirtide using a 5-drug cocktail in HIV-1 infected patients. Clinical Pharmacology and Therapeutics 73, 81.
67. Boyd, M. A., Zhang, X., Dorr, A. et al. (2003). Lack of enzyme-inducing effect of rifampicin on the pharmacolkinetics of enfuvirtide. Journal of Clinical Pharmacology 43,1382-91.
68. Sista, P., Melby, T., Dhingra, U. et al. (2001). The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. Antiviral Therapy 6, Suppl. 1, 3.
69. de Rosny, E., Vassell, R., Wingfield, P. T. et al. (2001). Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. Journal of Virology 75, 8859-63.
70. Hartt, J. K., Liang, T., Sahagun-Ruiz, A. et al. (2000). The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochemical and Biophysical Research Communications 272, 699-704.
71. Walmsley, S., Henry, K., Katlama, C. et al. (2003). Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. Journal of Infectious Diseases 188, 1827-33.
72. Villahermosa, M. L., Perez-Alvarez, L., Carmona, R. et al. (2003). Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS 17, 1083-6.
73. Zollner, B., Feucht, H. H., Schroter, M. et al. (2001). Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 15, 935-6.
74. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N. et al. (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. Journal of Virology 74, 8358-67.
75. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N. et al. (2001). Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. Journal of Virology 75, 8605-14.
76. Greenberg, M. L., Sista, P., Miralles, G. et al. (2002). Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II dose-ranging monotherapy trial of T-1249. Antiviral Therapy 7, Suppl. 1, S 106.
77. Sista, P., Melby, T., Greenberg, M. L. et al. (2002). Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials, substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antiviral Therapy 7, Suppl. 1, S16.
78. Su, C., Heilek-Snyder, G,, Fenger, D. et al. (2003). The relationship between susceptibility to enfuvirtide of baseline viral recombinants and polymorphisms in the env region of R5-tropic HIV-1. Antiviral Therapy 8, S59.
79. Sista, P., Melby, T., Greenberg, M. L. et al. (2003). Subgroup analysis of baseline (BL) susceptibility and early virological response to enfuvirtide in the combined TORO studies. Antiviral Therapy 8, S60.
80. Greenberg, M. L., Melby, T., Sista, P. et al. (2003). Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. In Proceedings of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 10-14 February 2003, Abstract 141, p. 108. Foundation for Retrovirology and Human Health, Alexandra, VA, USA.
81. Greenberg, M. L., McDanal, C. B., Stanfield-Oakley, S. A. et al. (2001). Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. In Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA, 4-8 February 2001. Abstract 473. http//www.retroconference.org/2001/abstracts/abstracts/abstracts/473.htm.
82. Reeves, J. D., Gallo, S. A., Ahmad, N. et al. (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proceedings of the National Academy of Sciences, USA 99, 16249-54.
83. Furuta, R. A., Wild, C. T., Weng, Y. et al. (1998). Capture of an early fusion-active conformation of HIV-1 gp41. Nature Structural Biology 5, 276-9.
84. Whitcomb, J. M., Huang, W., Fransen, S. et al. (2003). Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two Phase III study populations. In Proceedings of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 10- 14 February 2003, Abstract 557, p. 255.
85. Stanfield-Oakley, S. A., Jeffrey, J., McDanal, C. B. et al. (2003). Determinants of susceptibility to enfuvirtide map to gp41 in enfuvirtide-naive HIV-1. Antiviral Therapy 8, S22.
86. Heil, M., Decker, J. M., Chen, J. et al. (2003). Analysis of patient-derived HIV-1 isolates suggests a novel mechanism for decreased sensitivity to inhibition by enfuvirtide and T-649. Antiviral Therapy 8, Suppl. 1, S408.
87. Wrin, T., Huang, W., Yap, J. et al. (2001). Evaluating HIV-1 co-receptor useage and inhibitors of virus entry using recombinant virus assays. Antiviral Therapy 6, Suppl. 1, 3.
88. Labrosse, B., Labernardiere, J. L., Dam, E. et al. (2003). Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. Journal of Virology 77, 1610-3.
89. Poveda, E., Rodes, B., Toro, C. et al. (2002). Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 16, 1959-61.
90. Rimsky, L. T., Shugars, D. C. & Matthews, T. J. (1998). Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. Journal of Virology 72, 986-93.
91. Wei, X., Decker, J. M., Liu, H. et al. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy 46, 1896-905.
92. Mink, M., Greenberg, M. L., Mosier, S. et al. (2002). Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: Analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. Antiviral Therapy 7, Suppl. 1, S24.
93. Johnson, V. A., Brun-Vezinet, F., Clotet, B. et al. (2003). Drug resistance mutations in HIV-1. Topics in HIV Medicine 11, 215-21.
94. Xu, L., Pozniak, A., Wildfire, A. et al. (2004). Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuvirtide therapy. In Proceedings of the Eleventh Conference on Retroviruses and Oppoprtunistic Infections, San Francisco, CA, USA, 8-11 February 2004, Abstract 659, p. 305. Foundation for Retrovirology and Human Health, Alexandra, VA, USA.
95. Roman, F., Gonzalez, D., Lambert, C. et al. (2003). Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. Journal of Acquired Immune Deficiency Syndrome 33, 134-9.
96. Wheeler, D. A., Lalezari, J. P., Kilby, J. M. et al. (2004). Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. Journal of Clinical Virology 30, 183-90.
97. Caumont, A., Garrigue, I., Pellegrin, J. L. et al. (2001). Polymorphism of HIV-1 gp 41 protein in naive and highly active antiretroviral therapy (HAART) experienced patients. In Proceedings of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 15-19 December 2001, Abstract 1771. American Society for Microbiology, Washington, DC, USA.
98. Lu, J., Sista, P., Cammack, N. et al. (2002). Fitness of HIV-1 Clinical Isolates Resistant to T-20 (Enfuvirtide). Antiviral Therapy 7, Suppl. 1, S74.
99. Lu, J., Sista, P., Giguel, F. et al. (2004). Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). Journal of Virology 78, 4628-37.
100. Melby, T., Sista, P., Nelson, E. et al. (2002). Virological characterisation of patients through 48 weeks in T20-205 who acquired T-20 (enfuvirtide) resistance associated mutations during prior short-term enfuvirtide monotherapy. Antiviral Therapy 7, Suppl. 1, S77.
101. Lalezari, J. P., DeJesus, E., Northfelt, D. W. et al. (2003). A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir, and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Therapy 8, 279-87.